198 related articles for article (PubMed ID: 38764160)
1. Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation.
Gao Y; Zhou N; Liu J
Cancer Control; 2024; 31():10732748241255548. PubMed ID: 38764160
[TBL] [Abstract][Full Text] [Related]
2. The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer.
Balla A; Bhak J; Biró O
Mol Cell Probes; 2022 Dec; 66():101871. PubMed ID: 36283501
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsies based on DNA methylation as biomarkers for the detection and prognosis of lung cancer.
Li P; Liu S; Du L; Mohseni G; Zhang Y; Wang C
Clin Epigenetics; 2022 Sep; 14(1):118. PubMed ID: 36153611
[TBL] [Abstract][Full Text] [Related]
4. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.
Terp SK; Stoico MP; Dybkær K; Pedersen IS
Clin Epigenetics; 2023 Feb; 15(1):24. PubMed ID: 36788585
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
6. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
Luo H; Wei W; Ye Z; Zheng J; Xu RH
Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194
[TBL] [Abstract][Full Text] [Related]
7. Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers.
Miller BF; Pisanic Ii TR; Margolin G; Petrykowska HM; Athamanolap P; Goncearenco A; Osei-Tutu A; Annunziata CM; Wang TH; Elnitski L
Clin Epigenetics; 2020 Oct; 12(1):154. PubMed ID: 33081832
[TBL] [Abstract][Full Text] [Related]
8. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.
Giannopoulou L; Kasimir-Bauer S; Lianidou ES
Clin Chem Lab Med; 2018 Jan; 56(2):186-197. PubMed ID: 28753534
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
10. Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy.
Tomasetti M; Amati M; Neuzil J; Santarelli L
Lung Cancer; 2017 May; 107():65-72. PubMed ID: 27312601
[TBL] [Abstract][Full Text] [Related]
11. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy in lung cancer.
Li L; Jiang H; Zeng B; Wang X; Bao Y; Chen C; Ma L; Yuan J
Clin Chim Acta; 2024 Feb; 554():117757. PubMed ID: 38184141
[TBL] [Abstract][Full Text] [Related]
13. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer.
Widschwendter M; Zikan M; Wahl B; Lempiäinen H; Paprotka T; Evans I; Jones A; Ghazali S; Reisel D; Eichner J; Rujan T; Yang Z; Teschendorff AE; Ryan A; Cibula D; Menon U; Wittenberger T
Genome Med; 2017 Dec; 9(1):116. PubMed ID: 29268796
[TBL] [Abstract][Full Text] [Related]
14. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsies: DNA methylation analyses in circulating cell-free DNA.
Zeng H; He B; Yi C; Peng J
J Genet Genomics; 2018 Apr; 45(4):185-192. PubMed ID: 29706556
[TBL] [Abstract][Full Text] [Related]
16. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
[TBL] [Abstract][Full Text] [Related]
17. Potential clinical utility of liquid biopsies in ovarian cancer.
Zhu JW; Charkhchi P; Akbari MR
Mol Cancer; 2022 May; 21(1):114. PubMed ID: 35545786
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy in ovarian cancer.
Bhardwaj BK; Thankachan S; Venkatesh T; Suresh PS
Clin Chim Acta; 2020 Nov; 510():28-34. PubMed ID: 32622965
[TBL] [Abstract][Full Text] [Related]
19. RNA biomarkers from proximal liquid biopsy for diagnosis of ovarian cancer.
Hulstaert E; Levanon K; Morlion A; Van Aelst S; Christidis AA; Zamar R; Anckaert J; Verniers K; Bahar-Shany K; Sapoznik S; Vandesompele J; Mestdagh P
Neoplasia; 2022 Feb; 24(2):155-164. PubMed ID: 34998206
[TBL] [Abstract][Full Text] [Related]
20. Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.
Cheng X; Zhang L; Chen Y; Qing C
J Ovarian Res; 2017 Nov; 10(1):75. PubMed ID: 29132396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
